 | • レポートコード：MRC2312MG12609 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、64ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥481,000 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥721,500 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界のエピジェネティック治療市場規模と予測を収録しています。・世界のエピジェネティック治療市場：売上、2018年-2023年、2024年-2029年 ・世界のエピジェネティック治療市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のエピジェネティック治療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「PRAP（ホスホリボシルピロリン酸アミドトランスフェラーゼ）阻害剤」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 エピジェネティック治療のグローバル主要企業は、Astrazeneca、 Bristol-Myers Squibb、 Clovis Oncology、 Gsk Plc、 Incyte、 Ipsen、 Seagen、 Servier Laboratories, Ltd.などです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、エピジェネティック治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のエピジェネティック治療市場：タイプ別、2018年-2023年、2024年-2029年 世界のエピジェネティック治療市場：タイプ別市場シェア、2022年 ・PRAP（ホスホリボシルピロリン酸アミドトランスフェラーゼ）阻害剤、キナーゼ阻害剤、IDH（イソクエン酸脱水素酵素）阻害剤、HDAC（ヒストン脱アセチル化酵素）阻害剤、DNMT（DNAメチルトランスフェラーゼ）阻害剤 世界のエピジェネティック治療市場：用途別、2018年-2023年、2024年-2029年 世界のエピジェネティック治療市場：用途別市場シェア、2022年 ・病院、クリニック、その他 世界のエピジェネティック治療市場：地域・国別、2018年-2023年、2024年-2029年 世界のエピジェネティック治療市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるエピジェネティック治療のグローバル売上、2018年-2023年 ・主要企業におけるエピジェネティック治療のグローバル売上シェア、2022年 ・主要企業におけるエピジェネティック治療のグローバル販売量、2018年-2023年 ・主要企業におけるエピジェネティック治療のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Astrazeneca、 Bristol-Myers Squibb、 Clovis Oncology、 Gsk Plc、 Incyte、 Ipsen、 Seagen、 Servier Laboratories, Ltd. ************************************************************* ・調査・分析レポートの概要 エピジェネティック治療市場の定義 市場セグメント 世界のエピジェネティック治療市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のエピジェネティック治療市場規模 世界のエピジェネティック治療市場規模：2022年 VS 2029年 世界のエピジェネティック治療市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのエピジェネティック治療の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のエピジェネティック治療製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：PRAP（ホスホリボシルピロリン酸アミドトランスフェラーゼ）阻害剤、キナーゼ阻害剤、IDH（イソクエン酸脱水素酵素）阻害剤、HDAC（ヒストン脱アセチル化酵素）阻害剤、DNMT（DNAメチルトランスフェラーゼ）阻害剤 エピジェネティック治療のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、クリニック、その他 エピジェネティック治療の用途別グローバル売上・予測 ・地域別市場分析 地域別エピジェネティック治療市場規模 2022年と2029年 地域別エピジェネティック治療売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Astrazeneca、 Bristol-Myers Squibb、 Clovis Oncology、 Gsk Plc、 Incyte、 Ipsen、 Seagen、 Servier Laboratories, Ltd. ... |
This research report provides a comprehensive analysis of the Epigenetic Therapeutics market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Epigenetic Therapeutics market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Epigenetic Therapeutics, challenges faced by the industry, and potential opportunities for market players.
The global Epigenetic Therapeutics market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Epigenetic Therapeutics market presents opportunities for various stakeholders, including Hospital, Clinic. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Epigenetic Therapeutics market. Additionally, the growing consumer demand present avenues for market expansion.
The global Epigenetic Therapeutics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
Key Features:
The research report on the Epigenetic Therapeutics market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Epigenetic Therapeutics market.
Market Overview: The report provides a comprehensive overview of the Epigenetic Therapeutics market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., PRAP (Phosphoribosyl Pyrophosphate Amidotransferase) Inhibitor, Kinase Inhibitor), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Epigenetic Therapeutics market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Epigenetic Therapeutics market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Epigenetic Therapeutics market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Epigenetic Therapeutics market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Epigenetic Therapeutics market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Epigenetic Therapeutics market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Epigenetic Therapeutics, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Epigenetic Therapeutics market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Epigenetic Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
PRAP (Phosphoribosyl Pyrophosphate Amidotransferase) Inhibitor
Kinase Inhibitor
IDH (Isocitrate Dehydrogenase) Inhibitor
HDAC (Histone Deacetylase) Inhibitor
DNMT (DNA Methyltransferase) Inhibitor
Market segment by Application
Hospital
Clinic
Others
Global Epigenetic Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Astrazeneca
Bristol-Myers Squibb
Clovis Oncology
Gsk Plc
Incyte
Ipsen
Seagen
Servier Laboratories, Ltd.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Epigenetic Therapeutics, market overview.
Chapter 2: Global Epigenetic Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Epigenetic Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Epigenetic Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Epigenetic Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Epigenetic Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Epigenetic Therapeutics Overall Market Size
2.1 Global Epigenetic Therapeutics Market Size: 2022 VS 2029
2.2 Global Epigenetic Therapeutics Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Epigenetic Therapeutics Players in Global Market
3.2 Top Global Epigenetic Therapeutics Companies Ranked by Revenue
3.3 Global Epigenetic Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Epigenetic Therapeutics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Epigenetic Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Epigenetic Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Epigenetic Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Epigenetic Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Epigenetic Therapeutics Market Size Markets, 2022 & 2029
4.1.2 PRAP (Phosphoribosyl Pyrophosphate Amidotransferase) Inhibitor
4.1.3 Kinase Inhibitor
4.1.4 IDH (Isocitrate Dehydrogenase) Inhibitor
4.1.5 HDAC (Histone Deacetylase) Inhibitor
4.1.6 DNMT (DNA Methyltransferase) Inhibitor
4.2 By Type – Global Epigenetic Therapeutics Revenue & Forecasts
4.2.1 By Type – Global Epigenetic Therapeutics Revenue, 2018-2023
4.2.2 By Type – Global Epigenetic Therapeutics Revenue, 2024-2029
4.2.3 By Type – Global Epigenetic Therapeutics Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Epigenetic Therapeutics Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application – Global Epigenetic Therapeutics Revenue & Forecasts
5.2.1 By Application – Global Epigenetic Therapeutics Revenue, 2018-2023
5.2.2 By Application – Global Epigenetic Therapeutics Revenue, 2024-2029
5.2.3 By Application – Global Epigenetic Therapeutics Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Epigenetic Therapeutics Market Size, 2022 & 2029
6.2 By Region – Global Epigenetic Therapeutics Revenue & Forecasts
6.2.1 By Region – Global Epigenetic Therapeutics Revenue, 2018-2023
6.2.2 By Region – Global Epigenetic Therapeutics Revenue, 2024-2029
6.2.3 By Region – Global Epigenetic Therapeutics Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Epigenetic Therapeutics Revenue, 2018-2029
6.3.2 US Epigenetic Therapeutics Market Size, 2018-2029
6.3.3 Canada Epigenetic Therapeutics Market Size, 2018-2029
6.3.4 Mexico Epigenetic Therapeutics Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Epigenetic Therapeutics Revenue, 2018-2029
6.4.2 Germany Epigenetic Therapeutics Market Size, 2018-2029
6.4.3 France Epigenetic Therapeutics Market Size, 2018-2029
6.4.4 U.K. Epigenetic Therapeutics Market Size, 2018-2029
6.4.5 Italy Epigenetic Therapeutics Market Size, 2018-2029
6.4.6 Russia Epigenetic Therapeutics Market Size, 2018-2029
6.4.7 Nordic Countries Epigenetic Therapeutics Market Size, 2018-2029
6.4.8 Benelux Epigenetic Therapeutics Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Epigenetic Therapeutics Revenue, 2018-2029
6.5.2 China Epigenetic Therapeutics Market Size, 2018-2029
6.5.3 Japan Epigenetic Therapeutics Market Size, 2018-2029
6.5.4 South Korea Epigenetic Therapeutics Market Size, 2018-2029
6.5.5 Southeast Asia Epigenetic Therapeutics Market Size, 2018-2029
6.5.6 India Epigenetic Therapeutics Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Epigenetic Therapeutics Revenue, 2018-2029
6.6.2 Brazil Epigenetic Therapeutics Market Size, 2018-2029
6.6.3 Argentina Epigenetic Therapeutics Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Epigenetic Therapeutics Revenue, 2018-2029
6.7.2 Turkey Epigenetic Therapeutics Market Size, 2018-2029
6.7.3 Israel Epigenetic Therapeutics Market Size, 2018-2029
6.7.4 Saudi Arabia Epigenetic Therapeutics Market Size, 2018-2029
6.7.5 UAE Epigenetic Therapeutics Market Size, 2018-2029
7 Epigenetic Therapeutics Companies Profiles
7.1 Astrazeneca
7.1.1 Astrazeneca Company Summary
7.1.2 Astrazeneca Business Overview
7.1.3 Astrazeneca Epigenetic Therapeutics Major Product Offerings
7.1.4 Astrazeneca Epigenetic Therapeutics Revenue in Global Market (2018-2023)
7.1.5 Astrazeneca Key News & Latest Developments
7.2 Bristol-Myers Squibb
7.2.1 Bristol-Myers Squibb Company Summary
7.2.2 Bristol-Myers Squibb Business Overview
7.2.3 Bristol-Myers Squibb Epigenetic Therapeutics Major Product Offerings
7.2.4 Bristol-Myers Squibb Epigenetic Therapeutics Revenue in Global Market (2018-2023)
7.2.5 Bristol-Myers Squibb Key News & Latest Developments
7.3 Clovis Oncology
7.3.1 Clovis Oncology Company Summary
7.3.2 Clovis Oncology Business Overview
7.3.3 Clovis Oncology Epigenetic Therapeutics Major Product Offerings
7.3.4 Clovis Oncology Epigenetic Therapeutics Revenue in Global Market (2018-2023)
7.3.5 Clovis Oncology Key News & Latest Developments
7.4 Gsk Plc
7.4.1 Gsk Plc Company Summary
7.4.2 Gsk Plc Business Overview
7.4.3 Gsk Plc Epigenetic Therapeutics Major Product Offerings
7.4.4 Gsk Plc Epigenetic Therapeutics Revenue in Global Market (2018-2023)
7.4.5 Gsk Plc Key News & Latest Developments
7.5 Incyte
7.5.1 Incyte Company Summary
7.5.2 Incyte Business Overview
7.5.3 Incyte Epigenetic Therapeutics Major Product Offerings
7.5.4 Incyte Epigenetic Therapeutics Revenue in Global Market (2018-2023)
7.5.5 Incyte Key News & Latest Developments
7.6 Ipsen
7.6.1 Ipsen Company Summary
7.6.2 Ipsen Business Overview
7.6.3 Ipsen Epigenetic Therapeutics Major Product Offerings
7.6.4 Ipsen Epigenetic Therapeutics Revenue in Global Market (2018-2023)
7.6.5 Ipsen Key News & Latest Developments
7.7 Seagen
7.7.1 Seagen Company Summary
7.7.2 Seagen Business Overview
7.7.3 Seagen Epigenetic Therapeutics Major Product Offerings
7.7.4 Seagen Epigenetic Therapeutics Revenue in Global Market (2018-2023)
7.7.5 Seagen Key News & Latest Developments
7.8 Servier Laboratories, Ltd.
7.8.1 Servier Laboratories, Ltd. Company Summary
7.8.2 Servier Laboratories, Ltd. Business Overview
7.8.3 Servier Laboratories, Ltd. Epigenetic Therapeutics Major Product Offerings
7.8.4 Servier Laboratories, Ltd. Epigenetic Therapeutics Revenue in Global Market (2018-2023)
7.8.5 Servier Laboratories, Ltd. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer